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Abstract
The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia
have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly
diagnosed AML patients (age range, 18–86 years) who had received induction chemotherapy. Among 771 patients not
selected by genetics, the ELN-2017 classification re-assigned 26.5% of patients into a more favorable or, more commonly, a
more adverse-risk group compared with the ELN-2010 recommendations. Forty percent of the cohort, and 51% of patients
≥60 years, were classified as adverse-risk by ELN-2017. In 599 patients <60 years, estimated 5-year overall survival (OS)
was 64% for ELN-2017 favorable, 42% for intermediate-risk and 20% for adverse-risk patients. Among 517 patients aged
≥60 years, corresponding 5-year OS rates were 37, 16, and 6%. Patients with biallelic CEBPA mutations or inv(16) had
particularly favorable outcomes, while patients with mutated TP53 and a complex karyotype had especially poor prognosis.
DNMT3A mutations associated with inferior OS within each ELN-2017 risk group. Our results validate the prognostic
significance of the revised ELN-2017 risk classification in AML patients receiving induction chemotherapy across a broad
age range. Further refinement of the ELN-2017 risk classification is possible.
Introduction
In 2010, an international expert panel on behalf of the
European LeukemiaNet (ELN) published guidelines for the
diagnosis and management of acute myeloid leukemia
(AML) in adults [1]. In this initial version of the ELN
guidelines, a standardized reporting system for genetic
alterations was proposed that integrated cytogenetic and
molecular data to classify patients into four genetic groups.
Subsequent studies showed this classification is prog-
nostically relevant in intensively treated AML patients
[2, 3]. The ELN-2010 genetic classification has
* Klaus H. Metzeler
klaus.metzeler@med.uni-muenchen.de
1 Laboratory for Leukemia Diagnostics, Department of Medicine III,
University Hospital, LMU Munich, Munich, Germany
2 German Cancer Consortium (DKTK), Partner Site Munich,
Munich, Germany
3 German Cancer Research Center (DKFZ), Heidelberg, Germany
4 Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz
Zentrum München, German Research Center for Environmental
Health (HMGU), Munich, Germany
5 Institute of Biostatistics and Clinical Research, Westfälische
Wilhelms-Universität Münster, Münster, Germany
6 Department of Molecular Medicine and Pathology, University of
Auckland, Auckland, New Zealand
7 Department of Oncology and Hematology, Hospital Barmherzige
Brüder, Regensburg, Germany
8 Charité University Hospital Berlin, Berlin, Germany
9 Hospital Leverkusen, Leverkusen, Germany
10 Department of Medicine A, University Hospital Münster,
Münster, Germany
Supplementary information The online version of this article (https://
doi.org/10.1038/s41375-020-0806-0) contains supplementary















subsequently found widespread adoption in clinical practice
and in clinical trials.
In 2017, an updated version of the ELN recommenda-
tions has been published [4]. The ELN-2017 guidelines
include an updated genetic risk stratification system incor-
porating additional cytogenetic and molecular prognostic
factors. In the ELN-2017 risk stratification, the distinction
between the Intermediate-I category (including only
patients with normal cytogenetics) and the intermediate-II
category (including patients with intermediate-risk abnor-
mal karyotypes) has been eliminated, and consequently the
number of risk categories has been reduced from four to
three. Other major changes in the ELN-2017 classification
include the addition of mutations in three genes (ASXL1,
RUNX1 and TP53) that are now considered adverse genetic
markers, stratification of patients with FLT3 internal tandem
duplications (ITD) based on the ITD-to-wild-type allelic
ratio, and the recognition that only biallelic, but not
monoallelic, CEBPA mutations associate with favorable
outcomes. In contrast to the ELN-2010 classification, the
use of gene mutations for risk stratification is no longer
restricted to patients with normal cytogenetics, reflecting the
growing body of data on the prognostic relevance of gene
mutations in AML.
While each individual cytogenetic and molecular marker
included in the ELN-2017 classification has been repeatedly
and convincingly shown to associate with patient outcomes,
few studies so far have attempted to validate the proposed
new classification on the whole [5, 6]. Importantly, existing
validation studies were limited to younger AML patients,
and one study excluded certain genetic subsets (CEBPA-
mutated patients) [5]. Therefore, a comprehensive valida-
tion of the revised ELN-2017 classification in a large cohort
of intensively treated younger and older AML patients is
still lacking. We set out to test the prognostic relevance of
the ELN-2017 risk groups in AML patients receiving
induction chemotherapy on clinical trials, and to compare
the revised risk categories to the ELN-2010 genetic groups.
Our study provides a reference data set for future studies
employing the ELN-2017 classification.
Subjects and methods
Patients and inclusion criteria
Our study included a total of 1116 previously untreated
adult AML patients who had been enrolled on two sub-
sequent multicenter phase III trials of the German AML
Cooperative Group (AMLCG-1999, clinicaltrials.gov iden-
tifier NCT00266136, n= 857; and AMLCG-2008,
NCT01382147, n= 259) [7–9]. Treatment regimens are
summarized in the Supplementary Methods and
Supplementary Fig. 1. AML was diagnosed according to
World Health Organization (WHO) 2008 criteria [10]. The
present analysis includes 771 patients selected solely based
on the availability of cytogenetic data and a suitable bone
marrow (BM) or peripheral blood (PB) specimen for
mutation testing. An extension cohort of 345 patients with
cytogenetically normal AML (CN-AML) treated on the
AMLCG-1999 trial was included in the outcome analyses.
These patients were not included in analyses of patient
proportions assigned into the various ELN risk groups, or in
analyses of patient reclassification between the ELN-2010
and ELN-2017 recommendations, to avoid bias due to an
overrepresentation of CN-AML. All study protocols were in
accordance with the Declaration of Helsinki and approved
by the institutional review boards of participating centers.
All patients provided written informed consent for inclusion
on the clinical trial and genetic analyses.
Genetic analyses, measurement of FLT3-ITD allelic
ratio, and risk group assignment
Metaphase cytogenetics were analyzed centrally. For
molecular analyses, mononuclear cells were enriched from
pretreatment BM or PB by Ficoll density gradient cen-
trifugation. Testing for NPM1 and CEBPA gene mutations
was performed from cDNA by polymerase chain reaction
(PCR) followed by melting curve analysis or fragment
analysis, respectively [11, 12]. FLT3 ITD-to-wild-type
allelic ratio was determined by PCR and fragment analy-
sis from gDNA [13]. Mutations in 68 genes recurrently
mutated in myeloid malignancies, including NPM1, FLT3,
CEBPA, ASXL1, RUNX1, and TP53, were identified by
targeted gDNA sequencing, with a limit of detection of 2%
variant allele frequency [14, 15]. Ambiguities in ELN-2017
risk group assignment were resolved as described in the
Supplement.
Statistics
We studied associations between ELN genetic groups and
other patient characteristics using Fisher’s exact test for
categorical and the Wilcoxon rank-sum test for continuous
variables. Analyses of treatment outcomes used commonly
accepted definitions of complete remission (CR), relapse-
free survival (RFS) and overall survival (OS) (Supplemen-
tary Methods) [4, 16]. For time-to-event analyses, we cal-
culated survival estimates using the Kaplan–Meier method
and compared groups by the log-rank test. We used multi-
variable logistic regression models to analyze factors asso-
ciated with achievement of CR, and Cox proportional
hazards models for survival endpoints. Statistical analyses
were performed using R version 3.5.2 (R Foundation for
Statistical Computing, Vienna, Austria).
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Results
Association of the ELN-2017 categories with
baseline demographics and comparison to the ELN-
2010 genetic groups
Among 771 newly diagnosed AML patients who were
selected solely based on the availability of material for genetic
analyses (median age, 57 years, range, 18–86 years), 272
(35%) were classified as favorable, 190 (25%) as inter-
mediate, and 309 (40%) as adverse-risk according to the
ELN-2017 recommendations (“baseline cohort”, Table 1).
ELN-2017 adverse-risk patients were significantly older
(median, 62 years) than intermediate- or favorable-risk
patients (median, 53 and 54 years, respectively; P < 0.0001).
Among patients <60 years of age, 41% were assigned to the
favorable-risk group, 28% were intermediate risk, and 31%
were adverse-risk. Among patients aged ≥60 years, only 28%
were favorable-risk, 21% intermediate risk, while 51%
belonged to the adverse-risk group (Fig. 1a). Of note, 47% of
male patients had adverse-risk features, compared with only
33% of women (Table 1, Supplementary Fig. 2A; P=
0.0002). This difference was largely due to a lower prevalence
of NPM1 mutations and higher prevalence of RUNX1 and
ASXL1 mutations among male patients (P < 0.0001, respec-
tively). Adverse-risk patients also more frequently had sec-
ondary AML, had lower leukocyte counts (Supplementary
Fig. 2B) and tended to have lower BM blast percentages
compared with intermediate- or favorable-risk patients.
Based on the previous ELN-2010 genetic groups, 244 of
the 771 patients (32%) were classified as favorable, 221
(29%) as intermediate-I, 142 (18%) as intermediate-II and 164
(21%) as adverse (Fig. 1b). In the ELN-2017 risk stratification
system, the distinction between the intermediate-I and
intermediate–II groups has been eliminated and the number of
categories reduced from four to three, complicating side-by-
side comparisons between the old and revised classification.
However, when the ELN-2010 intermediate-I and
intermediate-II groups were treated as one, the novel classi-
fication resulted in reclassification of 204 patients (26.5%)
into a higher or lower prognostic category (Supplementary
Table 1). The net effects were a 3.7 percentage point increase
in the proportion of patients classified as favorable, and an
18.8 percentage point increase in the proportion of patients
classified as adverse, while the proportion of patients classi-
fied into the intermediate-risk category decreased by 22.5
percentage points.
Outcomes of AML patients classified according to
the 2017 ELN risk stratification system
Outcome analyses included the previously described
“baseline cohort” of 771 patients and an extension cohort of
345 patients with CN-AML, a subset particularly affected
by the changes in the ELN-2017 classification, for a total of
1116 patients (“outcomes cohort”, Supplementary Table 2).
All patients had received cytarabine plus adriamycin or
mitoxantrone-based induction chemotherapy on phase III
clinical trials, and none of the FLT3-mutated patients had
received a tyrosine kinase inhibitor upfront. The median
follow-up for survivors was 98 months [17]. According to
the ELN-2017 recommendations, 422 patients in the out-
comes cohort (38%) were classified as favorable, 295 (26%)
as intermediate, and 399 (36%) as adverse-risk. Patients in
the favorable- and intermediate-risk categories had similar
remission rates, while adverse-risk patients had significantly
lower CR rates (Table 2). Patients in the favorable, inter-
mediate and adverse-risk categories showed progressively
worse RFS and OS (Table 2, Fig. 2). These associations
were also observed in the subgroups of patients aged <60
years (n= 599) or ≥60 years (n= 517) (Table 2, Fig. 3).
Even though the ELN-2017 classification almost doubled
the proportion of patients classified as adverse-risk com-
pared with the ELN-2010 recommendations, 5-year OS of
these patients was only 12% in the entire cohort and 6% in
older patients.
Since the ELN-2017 genetic risk groups show strong
associations with other baseline variables including patient
age, sex, leukocyte counts, and clinically defined secondary
or treatment related AML (sAML/tAML) (Table 1), we
constructed multivariable models adjusting for these factors.
In a model for CR, ELN-2017 favorable- and intermediate-
risk patients had similar odds of reaching remission, while
adverse-risk patients had a significantly lower CR rate
(Fig. 4a). Older age, higher leukocyte counts, and a clinical
diagnosis of sAML/tAML associated with lower CR rates
after adjustment for the ELN-2017 genetic categories. In a
model for RFS, the risk of relapse or death for ELN-2017
favorable-risk patients was less than half compared with the
intermediate-risk category, and adverse-risk patients had an
~1.5-fold higher risk (Fig. 4b). Older age and higher leu-
kocyte counts were also linked to shorter RFS, while sAML
or tAML were not associated with RFS after adjusting for
the other factors. Regarding OS, favorable-risk patients had
an ~50% reduced, and adverse-risk patients a 60%
increased risk of death relative to the intermediate-risk
group (Fig. 4c). Other factors associated with shorter sur-
vival were older age, higher leukocyte counts, and a diag-
nosis of tAML, but not sAML.
The ELN-2017 prognostic classification resulted in better
overall discrimination of risk groups compared with the
ELN-2010 genetic groups, as shown by higher time-
dependent areas under receiver-operating-characteristic
curves for RFS and OS (Supplementary Fig. 3) [18]. This
increase in prognostic value was due to the larger fractions
of patients identified as favorable- or adverse-risk by the
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Table 1 Patient characteristics according to ELN-2017 risk group.
ELN-2017 risk group
Variable Favorable Intermediate Adverse P
Patient number n= 272 n= 190 n= 309
Age [years], median (range) 53 (18–86) 54 (18–77) 62 (21–80) <0.0001
Male sex 113 (42%) 94 (49%) 181 (59%) 0.0002
Disease type 0.0006
De novo AML 248 (91%) 162 (85%) 244 (79%)
Secondary AML 12 (4%) 17 (9%) 44 (14%)
Therapy-related AML 12 (4%) 11 (6%) 21 (7%)
WBC [×109/L], median (range) 23.9 (0.9–316) 31.4 (0.6–486) 13.2 (0.5–406) <0.0001
Bone marrow blasts [%], median (range) 80 (6–100) 82 (10–100) 77 (9–100) 0.03
FAB category <0.0001
M0 2 6 32
M1 46 55 71
M2 83 39 93
M4 85 36 56
M5 27 36 27
M6 5 6 13
M7 1 1 2
Unknown 23 12 15
MRC cytogenetic risk category –
Favorable 81 (30%) 0 0
Intermediate 189 (69%) 184 (97%) 157 (51%)
Adverse 2 (1%) 6 (3%) 152 (49%)
ELN-2010 genetic group –
Favorable 225 (83%) 12 (6%) 7 (2%)
Intermediate-I 24 (9%) 114 (60%) 83 (27%)
Intermediate-II 23 (8%) 64 (34%) 55 (18%)
Adverse 0 0 164 (53%)
Gene mutations detected in pretreatment samplea
NPM1 160 (59%) 76 (40%) 8 (3%) <0.0001
FLT3-ITD 43 (16%) 92 (48%) 60 (19%) <0.0001
- Low allelic ratio 41 (15%) 16 (8%) 20 (6%)
- High allelic ratio 2 (1%) 76 (40%) 40 (13%)
CEBPA 42 (15%) 16 (8%) 8 (3%) <0.0001
- Mono-allelic 11 (4%) 16 (8%) 8 (3%)
- Bi-allelic 31 (11%) 0 0
RUNX1 3 (1%) 0 111 (36%) <0.0001
ASXL1 11 (4%) 2 (1%) 77 (25%) <0.0001
TP53 1 (<1%) 3 (2%) 71 (23%) <0.0001
DNMT3A 90 (33%) 86 (46%) 66 (21%) <0.0001
TET2 50 (18%) 33 (17%) 37 (12%) 0.07
IDH1 23 (8%) 13 (7%) 14 (5%) 0.15
IDH2 35 (13%) 26 (14%) 43 (14%) 0.93
NRAS 79 (29%) 27 (14%) 50 (16%) 0.0001
KRAS 19 (7%) 14 (7%) 15 (5%) 0.41
WT1 33 (12%) 34 (18%) 34 (11%) 0.08
SRSF2 14 (5%) 6 (3%) 55 (18%) <0.0001
PTPN11 34 (13%) 8 (4%) 30 (10%) 0.007
STAG2 6 (2%) 14 (7%) 34 (11%) 0.0001
BCOR 3 (1%) 12 (6%) 41 (13%) <0.0001
RAD21 23 (8%) 13 (7%) 7 (2%) 0.0020
KMT2A PTD 1 (<1%) 24 (13%) 31 (10%) <0.0001
KMT2A PTD status unknown 20 4 6
WBC white blood cell count, FAB French-American British classification, MRC British Medical Research Council, ELN European LeukemiaNet,
ITD internal tandem duplication, PTD partial tandem duplication.
aGenes mutated in ≥5% of patients in the baseline cohort are listed.
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ELN-2017 system, while RFS and OS of the ELN-2017
favorable, intermediate and adverse-risk groups remained
very similar to the ELN-2010 favorable, intermediate-I/II
and adverse-risk categories (Fig. 5). Detailed outcomes
analyses for patients re-classified into a lower-risk or
higher-risk category in the ELN-2017 classification com-
pared with the 2010 guidelines are provided in Supple-
mentary Fig. 4.
Postremission therapy
Overall, 664 patients in our cohort reached CR after
protocol-specified induction therapy. Among those, 109
underwent allogeneic stem cell transplantation (alloSCT)
and 46 underwent autologous transplantation (autoSCT)
while in first CR (CR1), and 509 received only che-
motherapy as postremission therapy (Supplementary
Table 2 Outcomes according to the ELN-2017 genetic risk groups.
ELN-2017 genetic risk group Complete remission RFS OS
n [%] P 5-year RFS, % (95% CI) P 5-year OS, % (95% CI) P
All patients (n= 1116)
Favorable (n= 422) 305 (72) <0.0001 53.4 (48.0–59.4) <0.0001 54.0 (49.4–59.1) <0.0001
Intermediate (n= 295) 195 (66) 25.8 (20.2–32.9) 30.6 (25.7–36.5)
Adverse (n= 399) 164 (41) 11.9 (7.8–18.4) 12.2 (9.3–16.0)
Age < 60 years (n= 599)
Favorable (n= 261) 196 (75) <0.0001 62.5 (55.9–69.8) <0.0001 64.2 (58.5–70.3) <0.0001
Intermediate (n= 171) 113 (66) 36.6 (28.6–46.8) 41.5 (34.6–49.7)
Adverse (n= 167) 72 (43) 22.4 (14.5–34.6) 20.1 (14.7–27.5)
Age ≥ 60 years (n= 517)
Favorable (n= 161) 109 (68) <0.0001 37.0 (28.8–47.5) <0.0001 37.4 (30.4–45.9) <0.0001
Intermediate (n= 124) 82 (66) 11.3 (6.1–21.0) 16.0 (10.6–24.2)
Adverse (n= 232) 92 (40) 3.7 (1.2–11.9) 6.4 (3.9–10.7)
ELN European LeukemiaNet, RFS relapse-free survival, OS overall survival, CI confidence interval.
Fig. 1 Distribution of ELN risk
categories among intensively
treated AML patients.
a Distribution of the ELN-2017
risk categories in intensively
treated AML patients aged <60
years (left) and in patients aged
≥60 years (right). b Comparison
of risk group assignment
according to the ELN-2010 and
ELN-2017 genetic groups, and
re-distribution of risk categories
with the updated classification.
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Fig. 3 Outcomes of patients according to the ELN-2017 genetic
risk groups, stratified by age group. a Relapse-free survival and
b overall survival according to ELN-2017 categories in 599 patients
aged <60 years. c Relapse-free survival and d overall survival
according to ELN-2017 categories in 517 patients aged ≥60 years.
Fig. 2 Outcomes of patients according to the ELN-2017 genetic risk groups. a Relapse-free survival and b overall survival according to the
ELN-2017 categories in the entire cohort of 1116 patients (age range, 18–86 years).
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Fig. 1). AlloSCT and autoSCT were performed in 25 and
12% of CR1 patients aged <60 years, respectively, com-
pared with only 4 and <1% of those aged ≥60 years (Sup-
plementary Fig. 5A). Therefore, analyses of outcomes
according to postremission treatment received were
restricted to CR1 patients younger than 60. Clinical char-
acteristics of this subgroup (n= 381) are shown in Sup-
plementary Table 3. Although most patients in our analysis
were treated before the widespread use of molecular genetic
risk factors for postremission therapy selection, there was a
trend towards more frequent use of alloSCT among ELN-
2017 adverse-risk compared with intermediate-risk or
favorable-risk patients (36% vs. 27% vs. 20%; P= 0.06;
Supplementary Fig. 5B).
Supplementary Figs. 6–8 depict RFS and OS of ELN-
2017 favorable, intermediate and adverse-risk patients
according to postremission therapy. In multivariable ana-
lyses adjusting for age, within each ELN-2017 risk group
Fig. 4 Multivariable analyses
of outcomes according to the
ELN-2017 genetic risk groups
and other pretreatment
prognostic variables. a Forrest
plot showing odds ratios from a
logistic regression model for
achievement of complete
remission. b Forrest plot
showing hazard ratios from a
Cox proportional hazards model
for relapse-free survival.
c Forrest plot showing hazard
ratios from a Cox proportional
hazards model for overall
survival. Interaction P values
refer to an interaction between
the ELN-2017 risk groups and
the respective variable. All
multivariable models were
stratified according to trial and
induction therapy arm to account
for potential differences in
baseline risk between trials.
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patients receiving alloSCT in CR1 had longer RFS com-
pared with those receiving chemotherapy. However,
alloSCT associated with improved OS only in the adverse-
risk group (P= 0.05). Intermediate-risk patients receiving
alloSCT in CR1 showed a nonsignificant trend towards
improved OS, while in the favorable-risk group, OS was
similar for patients receiving alloSCT or chemotherapy
only. Of note, since postremission alloSCT assignment
was not randomized, other factors besides genetic risk may
have affected therapeutic decisions and thus biased these
results.
Outcomes of patients within genetic subsets of the
ELN-2017 categories
Outcomes of specific genetic subsets within the ELN-2017
risk categories are presented in detail in the Supplementary
Results, Supplementary Table 4, and Supplementary
Figs. 9–14. Overall, these analyses support the changes
introduced in the ELN-2017 guidelines, including the
revised risk stratification based on FLT3-ITD allelic ratio
and NPM1 mutation status as well as the inclusion of
ASXL1 and RUNX1 mutations as unfavorable markers.
Within the ELN-2017 favorable-risk group, patients with
inv(16)/t(16;16) or biallelic CEBPA mutations had superior
OS, with an estimated 5-year OS of 70% respectively,
compared with the other genetic subsets within this category
which achieved 5-year survival rates between 48 and 51%
(P= 0.0005, Supplementary Figs. 9A, B). On the other
hand, within the ELN-2017 adverse-risk category, patients
with complex karyotypes together with mutated TP53 had
particularly unfavorable outcomes with a 5-year RFS and
OS of 0% (Supplementary Fig. 9E, F).
Proposed refinement of the ELN-2017 prognostic
stratification system
Based on our analyses of genetic subsets within the ELN-
defined risk groups and previously published data [19–23],
we propose to further refine the ELN-2017 classification
without introducing additional markers, by separating a
“very favorable” subgroup (patients with inv(16)/t(16;16) or
biallelic CEBPA mutations; n= 82) from the favorable
category, and a “very adverse” subgroup (patients with
TP53 mutations and a complex karyotype; n= 62) from the
adverse category. Using this refined classification, CR rates
for the very favorable, favorable, intermediate, adverse and
very adverse groups were 77, 71, 66, 44 and 27%, respec-
tively (Supplementary Table 5). RFS and OS for the refined
ELN-2017 classification are shown in Fig. 6 and Supple-
mentary Fig. 15. Estimated OS rates at 5 years were 70%
for very favorable, 50% for favorable, 31% for intermediate,
14% for adverse and 0% for very adverse patients. In
multivariable analyses adjusting for potential confounders
(Supplementary Fig. 16), the very adverse group of the
refined classification had inferior CR rate, RFS and OS
compared with the adverse group. The very favorable-risk
subgroup had longer OS compared with the favorable
subgroup, although CR rate and RFS were not significantly
different. This OS difference was driven by survival after
relapse (Supplementary Fig. 17), which was significantly
longer for the very favorable compared with the favorable
(P= 0.018) and to all other subgroups (P= 0.005), con-
sistent with reports that patients with biCEBPA mutations
or inv(16) are particularly responsive to salvage therapy
[20, 24]. The proposed refinement of the ELN-2017 risk
groups was successfully validated in an independent cohort
Fig. 5 Outcomes of risk categories defined by ELN-2017 guidelines (solid lines) in comparison to the ELN-2010 risk categories (dashed
lines). a Relapse-free survival and b overall survival.
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of mostly younger AML patients treated on clinical trials of
the AML-SG study group [19] (n= 1540; 83% aged <60
years; Supplementary Methods and Supplementary Fig. 18).
We also tested whether the inclusion of additional gene
mutations can further refine the ELN-2017 risk groups, and
found that within each risk category mutated DNMT3A
identified a subgroup with significantly inferior OS com-
pared with DNMT3A wild-type patients (Supplementary
Results and Supplementary Figs. 19 and 20).
Discussion
Since the ELN recommendations for AML risk stratification
by genetics were revised in 2017, the updated classification
has been widely adopted. For example, the ELN-2017 risk
stratification has been incorporated into the U.S. National
Comprehensive Cancer Center Network (NCCN) clinical
practice guidelines for AML [25]. Nevertheless, it is
important to remember the ELN classification is an expert
consensus statement, based on a synthesis of retrospective
analyses from different cooperative groups, and mostly
involving patients who had received intensive chemother-
apy on clinical trials. While the individual prognostic
markers recognized in the ELN-2017 recommendations are
supported by retrospective studies, the entire risk stratifi-
cation system was not validated in the primary publication
[4]. Our retrospective analysis confirms that the ELN-2017
classification allows robust risk stratification of AML
patients receiving cytarabine plus anthracycline/anthrace-
nedione-based induction therapy. Compared with the
ELN-2010 reporting system, ELN-2017 improves risk
stratification by classifying more patients as favorable- or
adverse-risk groups, and thus leaving fewer patients in the
intermediate risk group. Thereby, the ELN-2017 classifi-
cation facilitates discussions with patients about their indi-
vidual prognosis at the time of initial diagnosis. We
demonstrate the ELN-2017 classification is applicable in
younger (<60 years) as well as in older (≥60 years) patients
receiving induction chemotherapy. Of note, the prognostic
relevance of the ELN-2017 categories is less clear in very
old patients (≥75 y) who still undergo intensive treatment
[26]. We observed that women were more likely to belong
to ELN favorable group, while men more often fell into the
adverse group due to a higher incidence of NPM1 mutations
and a lower incidence of ASXL1 and RUNX1 mutations in
females, as described previously [14, 27–29]. Population-
based analyses from the U.S. Surveillance, Epidemiology,
and End Result (SEER) database also show male
AML patients have worse OS [30], although analyses in
other countries did not identify sex-specific survival dif-
ferences [31].
Previously published studies suggest that the ELN-2017
prognostic groups can be further refined without including
additional genetic markers. For example, leukemias with the
core binding factor gene rearrangements, t(8;21) or inv(16)/t
(16;16), both have relatively favorable outcomes. However,
data from the CALGB and AML-SG study groups and the
SEER registry have suggested that OS of patients with inv
(16) is superior compared to those with t(8;21) [19–21],
although this difference was not observed in other large
cohorts [32]. Likewise, biallelic CEBPA mutations seem to
delineate a patient subgroup with particularly good out-
comes even compared with other favorable-risk groups
[19, 24]. Since our findings are in line with these previous
analyses, we suggest that the inv(16) and biallelic CEBPA-
Fig. 6 Outcomes of patients according to the proposed refinement of the ELN-2017 genetic risk groups. a Relapse-free survival and b overall
survival in the entire cohort of 1116 patients (age range, 18–86 years).
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mutated subgroups should be regarded as prognostically
“very favorable” with an expected 5-year OS of close to
80% in younger and 50% in older patients. On the other side
of the spectrum, complex chromosomal alterations associate
with poor outcomes. Within this group, “typical complex
karyotypes” (i.e., those with deletions affecting chromo-
some arms 5q, 7q, and/or 17p) frequently co-exist with
TP53 mutations, and those patients have particularly dismal
outcomes [22, 23]. In our cohort, none of the patients with
TP53 mutation and a complex karyotype achieved long-
term survival. Thus, the available data consistently show
that this genotype defines a “very unfavorable” subgroup
of AML.
Since current treatment guidelines suggest allogeneic
stem cell transplantation (alloSCT) as the preferred post-
remission treatment in suitable patients with adverse genetic
risk [4, 25], the updated ELN classification would be
expected to lead to an increase in the proportion of AML
patients considered for alloSCT in first remission. Due to
the enrollment period of the trials analyzed here, and since
many patients now assigned to the ELN-2017 adverse-risk
group were originally not classified as poor risk, <20% of
ELN-2017 adverse patients received an alloSCT while in
first remission. It is currently unclear if the increased pro-
portion of adverse-risk patients recommended to undergo
alloSCT will ultimately improve outcomes in this patient
population. Despite this uncertainty, the ELN-2017 adverse-
risk definition allows the identification of a large high-risk
subgroup of AML patients who clearly have suboptimal
outcomes with conventional induction chemotherapy. In
particular, patients in the “very unfavorable” subgroup
proposed here almost never achieve durable remissions
when treated with induction chemotherapy, even if it is
followed by allogeneic transplantation. We suggest these
patients should not be offered conventional intensive che-
motherapy and should be enrolled in clinical trials whenever
possible.
In this context, our data not only validate the use of the
ELN-2017 classification for pretreatment risk stratification in
intensively treated AML patients, but can also serve as a
benchmark for clinical trials evaluating novel therapeutic
strategies. It is important to keep in mind that risk classifi-
cation systems must always be interpreted in conjunction
with treatment regimens, which may change over time. The
studies that led to the ELN-2017 recommendations, as
well as our validation analysis, included AML patients
receiving traditional cytarabine-based induction chemother-
apy. The addition of targeted agents, such as FLT3 inhibitors
or inhibitors of mutated IDH1 or IDH2 [33, 34], to
standard induction therapy may alter the prognosis of
patients receiving these novel agents and thus prompt
changes in genetic risk classification. It is also uncertain if
the ELN-2017 risk groups are applicable in patients treated
with alternative first-line approaches such as hypomethy-
lating agents [35, 36], venetoclax-based regimens [37, 38],
novel targeted agents or immunotherapeutical approaches
[39, 40].
Finally, predictions of long-term treatment outcomes
based on pretreatment genetic characterization alone are far
from perfect (Supplementary Fig. 3). Age, comorbidities,
performance status and other important risk factors are not
reflected in the ELN categories [41]. Moreover, analyses of
measurable residual disease (MRD) during and after treat-
ment by flow cytometry, quantitative PCR or next-
generation sequencing have emerged as novel tools to
assess response to therapy and prognosis [42–45]. One
major current challenge thus is the development of algo-
rithms that integrate pretreatment risk factors and long-
itudinal MRD measurements to guide individualized AML
treatment. However, only prognostic factors that can be
determined at the time of diagnosis can be used to guide
selection of initial therapy. Our data demonstrate that pre-
treatment genetic risk stratification according to the ELN-
2017 criteria identifies patient subgroups with a high chance
of cure, as well as subgroups of patients who do not benefit
from induction chemotherapy. Therefore, pretreatment
genetic risk stratification will likely remain an integral part
of AML treatment algorithms.
In summary, our study provides the first independent
validation of the ELN-2017 recommendations for risk
stratification by genetics in a large cohort of patients across
a broad age range who were treated with induction che-
motherapy on clinical trials. Compared with the previous
ELN-2010 guidelines, the ELN-2017 recommendations
result in more patients being classified as favorable risk, and
significantly more patients classified as adverse-risk, and
thereby improve overall risk assessment. Further refinement
of the ELN-2017 classification is possible using variables
already considered in the current guidelines, or by including
additional genetic markers.
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